Downregulation of liver–intestine cadherin enhances cisplatin-induced apoptosis in human gastric cancer BGC823 cells. (February 2018)

• Record Type: Journal Article
• Authors: Liu, Meng; Han, Zheng; Zhu, Qing-Xi; Tan, Jie; Liu, Wei-Jie; Wang, Yan-Fen; Chen, Wei; Zou, Yan-Li; Cai, Yi-Shan; Tian, Xia; Huang, Xiaodong
• Is Part Of: Cancer gene therapy. Volume 25:Number 1/2(2018)
• Page Start: 1
• Page End: 9
• Publication Date: 2018-02
• Subjects: Cancer -- Gene therapy -- Periodicals; Gene therapy -- Periodicals; Gene Therapy -- Periodicals; Neoplasms -- therapy -- Periodicals; Electronic journals; 616.99406
• DOI: 10.1038/s41417-017-0001-2
• Languages: English
• ISSNs: 0929-1903

Abstract

Abstract Gastric cancer is the fourth most common type of cancer.Liver–intestine cadherin (CDH17 ) has been found to be involved in the proliferation and apoptosis of gastric cancer cells. Cisplatin is one of the most widely used antineoplastic agents in the treatment of solid tumor and hematological malignancies. However, the mechanism of enhancing cisplatin-inducing effects on human gastric cancer BGC823 cells by blockingCDH17 gene, both in vitro and in vivo, remains to be clarified. In this study, we investigated the signaling pathway by which cisplatin induces apoptosis by blockingCDH17 gene in gastric cancer BGC823 cells. Our results indicate that down-expression ofCDH17 gene can enhance apoptosis-inducing effects of cisplatin on human gastric cancer BGC823 cells. The expression levels of Bax and Cyt-c proteins were upregulated, but the expression levels of Bcl-2 and Bcl-xL proteins were downregulated by blockingCDH17 gene in gastric cancer BGC823 cells after treatment with cisplatin. Moreover, down-expression ofCDH17 enhanced the efficacy of cisplatin-induced inhibition of tumor growth in nude mice via apoptosis induction. Down-expression ofCDH17 gene can significantly improve apoptosis-inducing effects of cisplatin in vitro and in vivo, which is a new strategy to improve chemotherapeutic effects on gastric cancer.